Thomas A. McFarland, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. McFarland is a Clinical Professor of Medicine at the University of Wisconsin-Madison and is the Director of the UW combined Hematology/Oncology Fellowship program. He was the former Medical Director of the UW Carbone Cancer Center at 1 S. Park. Dr. McFarland holds a long tradition of teaching and developed the fellows' clinical rotation at the 1 South Park UWCCC. He has participated in the fellowship program for many years as a teacher and also served on many committees, prior to being appointed the Director.
Specialties
UW Health Clinics
Other Locations
Hospital Affiliation(s)
Languages Spoken
| English |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Internal Medicine
Hematology Medical Oncology |
| Fellowship |
Tufts-New England Medical Center, Boston, MA
|
| Residency |
Tufts-New England Medical Center, Boston, MA
|
| Internship |
Tufts-New England Medical Center, Boston, MA
|
| Medical School |
University of Illinois College of Medicine, Champaign-Urbana, 1987
|
Procedures
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
- Bone Marrow Biopsy
- Chemotherapy
- Lumbar Puncture
- Thoracentesis
| Research |
Dr. McFarland actively participates in hematology and oncology clinical trials. |
PubMed Articles
-
Cetnar J Wilding G McNeel D Loconte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
-
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS .
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
-
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS .
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 Sep;52(9):1675-80
[PubMed ID: 21864042]
-
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS .
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 May 17;
[PubMed ID: 21585283]
-
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G .
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
-
Morgan-Meadows S Mulkerin D Berlin JD Kim K Bailey H Saphner T Jumonville A Hansen R Ahuja H McFarland T Thomas JP .
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology. 2005;69(2):130-4
[PubMed ID: 16118509]










